[1]
|
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi: 10.3322/caac.21660 |
[2]
|
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391: 1023-1075. doi: 10.1016/S0140-6736(17)33326-3 |
[3]
|
Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33. doi: 10.3322/caac.21654 |
[4]
|
Wong MC, Goggins WB, Wang HH, et al. Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries[J]. Eur Urol, 2016, 70: 862-874. doi: 10.1016/j.eururo.2016.05.043 |
[5]
|
Draisma G, Etzioni R, Tsodikov A, et al. Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context[J]. J Natl Cancer Inst, 2009, 101: 374-383. doi: 10.1093/jnci/djp001 |
[6]
|
Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2: ERG gene fusion[J]. J Urol, 2012, 187: 795-801. doi: 10.1016/j.juro.2011.10.133 |
[7]
|
Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force[J]. JAMA, 2018, 319: 1914-1931. doi: 10.1001/jama.2018.3712 |
[8]
|
Eskra JN, Rabizadeh D, Pavlovich CP, et al. Approaches to urinary detection of prostate cancer[J]. Prostate Cancer Prostatic Dis, 2019, 22: 362-381. doi: 10.1038/s41391-019-0127-4 |
[9]
|
Bussemakers MJ, Van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer[J]. Cancer Res, 1999, 59: 5975-5979. |
[10]
|
Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis[J]. J Urol, 2013, 189: 422-429. doi: 10.1016/j.juro.2012.04.143 |
[11]
|
Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy[J]. Urology, 2007, 69: 532-535. doi: 10.1016/j.urology.2006.12.014 |
[12]
|
Ploussard G, de la Taille A. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection[J]. Expert Rev Anticancer Ther, 2018, 18: 1013-1020. doi: 10.1080/14737140.2018.1502086 |
[13]
|
Lee D, Shim SR, Ahn ST, et al. Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis[J]. Clin Genitourin Cancer, 2020, 18: 402-408. e5. doi: 10.1016/j.clgc.2020.03.005 |
[14]
|
Salciccia S, Capriotti AL, Laganà A, et al. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes[J]. Int J Mol Sci, 2021, 22: 4367. doi: 10.3390/ijms22094367 |
[15]
|
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer[J]. Science, 2005, 310: 644-648. doi: 10.1126/science.1117679 |
[16]
|
Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer[J]. Clin Cancer Res, 2007, 13: 5103-5108. doi: 10.1158/1078-0432.CCR-07-0700 |
[17]
|
Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer[J]. Eur Urol, 2014, 65: 534-542. doi: 10.1016/j.eururo.2012.11.014 |
[18]
|
Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2: ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment[J]. Eur Urol, 2016, 70: 45-53. doi: 10.1016/j.eururo.2015.04.039 |
[19]
|
Sanda MG, Feng Z, Howard DH, et al. Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer[J]. JAMA Oncol, 2017, 3: 1085-1093. doi: 10.1001/jamaoncol.2017.0177 |
[20]
|
Tosoian JJ, Trock BJ, Morgan TM, et al. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach[J]. J Urol, 2021, 205: 732-739. doi: 10.1097/JU.0000000000001430 |
[21]
|
Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J]. Oncogene, 2003, 22: 8031-8041. doi: 10.1038/sj.onc.1206928 |
[22]
|
Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22[J]. Oncotarget, 2016, 7: 63901-63912. doi: 10.18632/oncotarget.11564 |
[23]
|
Ren S, Peng Z, Mao JH, et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings[J]. Cell Res, 2012, 22: 806-821. doi: 10.1038/cr.2012.30 |
[24]
|
Wang F, Ren S, Chen R, et al. Development and prospec-tive multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer[J]. Oncotarget, 2014, 5: 11091-11102. doi: 10.18632/oncotarget.2691 |
[25]
|
Goyal B, Yadav SRM, Awasthee N, et al. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875: 188502. doi: 10.1016/j.bbcan.2021.188502 |
[26]
|
Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape[J]. N Engl J Med, 1985, 312: 338-343. doi: 10.1056/NEJM198502073120603 |
[27]
|
Bolduc S, Lacombe L, Naud A, et al. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL[J]. Can Urol Assoc J, 2007, 1: 377-381. https://www.nature.com/articles/nrurol.2009.261 |
[28]
|
Pannek J, Rittenhouse HG, Evans CL, et al. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer[J]. Urology, 1997, 50: 715-721. doi: 10.1016/S0090-4295(97)00324-5 |
[29]
|
Occhipinti S, Mengozzi G, Oderda M, et al. Low Levels of Urinary PSA Better Identify Prostate Cancer Patients[J]. Cancers (Basel), 2021, 13: 3570. doi: 10.3390/cancers13143570 |
[30]
|
Weir EG, Partin AW, Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry[J]. J Urol, 2000, 163: 1739-1742. doi: 10.1016/S0022-5347(05)67532-5 |
[31]
|
Augustin H, Hammerer PG, Graefen M, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy[J]. J Cancer Res Clin Oncol, 2003, 129: 662-668. doi: 10.1007/s00432-003-0496-9 |
[32]
|
Hammarsten P, Josefsson A, Thysell E, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome[J]. Mod Pathol, 2019, 32: 1310-1319. doi: 10.1038/s41379-019-0260-6 |
[33]
|
Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions[J]. J Extracell Vesicles, 2015, 4: 27066. doi: 10.3402/jev.v4.27066 |
[34]
|
Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extra-cellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7: 1535750. doi: 10.1080/20013078.2018.1535750 |
[35]
|
Zhang Y, Liu Y, Liu H, et al. Exosomes: biogenesis, biologic function and clinical potential[J]. Cell Biosci, 2019, 9: 19. doi: 10.1186/s13578-019-0282-2 |
[36]
|
Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers[J]. Proteomics Clin Appl, 2015, 9: 358-367. https://www.sciencedirect.com/science/article/pii/S0163725817300347 |
[37]
|
Donovan MJ, Noerholm M, Bentink S, et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result[J]. Prostate Cancer Prostatic Dis, 2015, 18: 370-375. doi: 10.1038/pcan.2015.40 |
[38]
|
Mckiernan J, Donovan MJ, O'neill V, et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy[J]. JAMA Oncol, 2016, 2: 882-889. doi: 10.1001/jamaoncol.2016.0097 |
[39]
|
Mckiernan J, Donovan MJ, Margolis E, et al. A Prospec-tive Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy[J]. Eur Urol, 2018, 74: 731-738. https://www.sciencedirect.com/science/article/pii/S0302283818306043 |
[40]
|
Mckiernan J, Noerholm M, Tadigotla V, et al. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy[J]. BMC Urol, 2020, 20: 138. doi: 10.1186/s12894-020-00712-4 |
[41]
|
Catalanotto C, Cogoni C, Zardo G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions[J]. Int J Mol Sci, 2016, 17: 1712. doi: 10.3390/ijms17101712 |
[42]
|
Bertoli G, Cava C, Castiglioni I. MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer[J]. Int J Mol Sci, 2016, 17: 421. doi: 10.3390/ijms17030421 |
[43]
|
Samsonov R, Shtam T, Burdakov V, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic[J]. Prostate, 2016, 76: 68-79. |
[44]
|
Foj L, Ferrer F, Serra M, et al. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis[J]. Prostate, 2017, 77: 573-583. |
[45]
|
Rodríguez M, Bajo-Santos C, Hessvik NP, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes[J]. Mol Cancer, 2017, 16: 156. doi: 10.1186/s12943-017-0726-4 |
[46]
|
Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations[J]. Nature, 2020, 580: 93-99. |